Should I buy or sell Protara Therapeutics stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Protara Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" TARA shares. View TARA analyst ratings or view top-rated stocks .

What is Protara Therapeutics' stock price target for 2024?

1 Wall Street research analysts have issued 12-month price targets for Protara Therapeutics' shares. Their TARA share price targets range from $23.00 to $23.00. On average, they predict the company's stock price to reach $23.00 in the next year. This suggests a possible upside of 745.6% from the stock's current price. View analysts price targets for TARA or view top-rated stocks among Wall Street analysts .

How have TARA shares performed in 2024?

Protara Therapeutics' stock was trading at $1.8751 at the beginning of 2024. Since then, TARA stock has increased by 45.1% and is now trading at $2.72. View the best growth stocks for 2024 here .

When is Protara Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our TARA earnings forecast .

How were Protara Therapeutics' earnings last quarter?

Protara Therapeutics, Inc. (NASDAQ:TARA) posted its quarterly earnings data on Wednesday, March, 13th. The company reported ($0.90) EPS for the quarter, topping the consensus estimate of ($1.03) by $0.13.

What other stocks do shareholders of Protara Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Protara Therapeutics investors own include Immunic (IMUX) , Trevena (TRVN) , AIM ImmunoTech (AIM) , Chimerix (CMRX) , CTI BioPharma (CTIC) , Fortress Biotech (FBIO) , Genocea Biosciences (GNCA) and Otonomy (OTIC) .

How do I buy shares of Protara Therapeutics?

Shares of TARA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:TARA

Protara Therapeutics (TARA) Stock Price, News & Analysis

→ [Urgent!] Generational Wealth Gameplan (From Crypto 101 Media) (Ad)

Free TARA Stock Alerts

$2.72

-0.01 (-0.37%)

(As of 01:44 PM ET)

Compare

Today's Range: $2.66
▼
$2.89
50-Day Range: $2.73
▼
$4.83
52-Week Range: $1.04
▼
$5.24

Volume: 202,725 shs
Average Volume: 205,518 shs
Market Capitalization: $31.09 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $23.00

Get Protara Therapeutics alerts:

Protara Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 745.6% Upside
$23.00 Price Target
Short Interest: Healthy
0.71% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.33
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($3.56) to ($4.48) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.97 out of 5 stars

Medical Sector

567th out of 914 stocks

Biological Products, Except Diagnostic Industry

95th out of 152 stocks

3.5

Analyst's Opinion

Consensus Rating
Protara Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Protara Therapeutics has only been the subject of 1 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
0.71% of the float of Protara Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Protara Therapeutics has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Protara Therapeutics has recently increased by 6.19%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Protara Therapeutics does not currently pay a dividend.
Dividend Growth
Protara Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for TARA.

2.4

News and Social Media Coverage

News Sentiment
Protara Therapeutics has a news sentiment score of 0.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.49 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Protara Therapeutics this week, compared to 0 articles on an average week.
Search Interest
Only 2 people have searched for TARA on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
MarketBeat Follows
3 people have added Protara Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Protara Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
18.40% of the stock of Protara Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 38.13% of the stock of Protara Therapeutics is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Protara Therapeutics are expected to decrease in the coming year, from ($3.56) to ($4.48) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Protara Therapeutics is -0.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Protara Therapeutics is -0.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Protara Therapeutics has a P/B Ratio of 0.45. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Crypto 101 Media

[Urgent!] Generational Wealth Gameplan

A brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market.

Click here to get instant access to the guide

About Protara Therapeutics Stock (NASDAQ:TARA)

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed its name to Protara Therapeutics, Inc. in May 2020. The company is headquartered in New York, New York.

TARA Stock Price History

30 days | 90 days | 365 days | Advanced Chart

TARA Stock News Headlines

April 17, 2024 | msn.com

Protara Therapeutics (TARA) Price Target Decreased by 11.76% to 27.54

April 15, 2024 | finance.yahoo.com

Protara Therapeutics, Inc. (TARA)

April 18, 2024 | Crypto 101 Media (Ad)

[Urgent!] Generational Wealth Gameplan

A brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market.

April 9, 2024 | americanbankingnews.com

Protara Therapeutics (NASDAQ:TARA) Stock Rating Reaffirmed by HC Wainwright

April 9, 2024 | markets.businessinsider.com

Buy Rating for Protara Therapeutics’ TARA-002 Based on Promising Clinical Data and Market Potential in NMIBC Treatment

April 5, 2024 | msn.com

Protara Therapeutics Shares Interim Data From Bladder Cancer Study, Raises $45M Via Equity

April 5, 2024 | markets.businessinsider.com

Protara Reaches Alignment With FDA On A Registrational Path Forward For IV Choline Chloride

April 5, 2024 | markets.businessinsider.com

Protara Announces Positive Data From TARA-002 Trial In Bladder Cancer; Stock Up

April 18, 2024 | Crypto 101 Media (Ad)

[Urgent!] Generational Wealth Gameplan

A brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market.

April 5, 2024 | globenewswire.com

Protara Therapeutics Announces Oversubscribed $45 Million Private Placement Financing

April 5, 2024 | globenewswire.com

Protara Therapeutics Announces Alignment with FDA on Registrational Path Forward for IV Choline Chloride in Patients Dependent on Parenteral Nutrition

April 5, 2024 | globenewswire.com

Protara Therapeutics Announces Positive Three-Month Data from TARA-002 Clinical Program in NMIBC

March 23, 2024 | investorplace.com

3 Stocks That Could Help You Retire on a Private Island

March 13, 2024 | markets.businessinsider.com

Buy Rating on Protara Therapeutics Backed by Promising TARA-002 Clinical Trials and Significant Market Opportunity

March 13, 2024 | chron.com

Protara Therapeutics: Q4 Earnings Snapshot

March 13, 2024 | globenewswire.com

Protara Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

March 3, 2024 | finance.yahoo.com

TARA May 2024 2.500 put

March 3, 2024 | finance.yahoo.com

TARA Aug 2024 7.500 call

February 28, 2024 | theglobeandmail.com

Non Muscle Invasive Bladder Cancer Pipeline Outlook Report 2024

February 28, 2024 | globenewswire.com

Protara Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference

February 22, 2024 | msn.com

NorthSea Therapeutics commences Phase IIa trial for IFALD therapy

February 17, 2024 | finance.yahoo.com

We're Keeping An Eye On Protara Therapeutics' (NASDAQ:TARA) Cash Burn Rate

January 25, 2024 | seekingalpha.com

CG Oncology's Lead Bladder Cancer Drug Offers A Strong Potential Revenue Stream With Buyout Optionality

December 2, 2023 | markets.businessinsider.com

Oppenheimer Reaffirms Their Buy Rating on Protara Therapeutics (TARA)

November 30, 2023 | finance.yahoo.com

Protara Therapeutics Announces Presentation of Additional Encouraging Data from Phase 1a ADVANCED-1 Trial of TARA-002 in NMIBC at the 24th Annual Meeting of the Society of Urologic Oncology

November 5, 2023 | benzinga.com

Protara Therapeutics Stock (NASDAQ:TARA) Earnings Dates and Earning Calls

November 5, 2023 | msn.com

Protara Therapeutics reports Q3 results

See More Headlines

Receive TARA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Protara Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/13/2024
Today: 4/18/2024
Next Earnings (Estimated): 5/02/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Current Symbol: NASDAQ:TARA
CUSIP: N/A
CIK: 1359931
Web: www.proteontherapeutics.com
Phone: (646) 844-0337
Fax: 781-487-6729
Employees: 26
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $23.00
High Stock Price Target: $23.00
Low Stock Price Target: $23.00
Potential Upside/Downside: +742.5%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($3.57)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-40,420,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -49.71%
Return on Assets: -43.82%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 11.17
Quick Ratio: 11.17

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $6.01 per share
Price / Book: 0.45

Miscellaneous

Outstanding Shares: 11,434,000
Free Float: 9,330,000
Market Cap: $31.21 million
Optionable: Optionable
Beta: 1.71

10 Best Stocks to Own in 2024

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

Mr. Jesse Shefferman (Age 52)
Co-Founder, CEO, President & Director
Comp: $1.11M
Dr. Jacqueline Zummo M.B.A. (Age 43)
M.P.H., Ph.D., Co-Founder, Senior VP & Chief Scientific Operations Officer
Comp: $743.68k
Mr. Patrick Fabbio M.B.A. (Age 56)
Chief Financial Officer
Ms. Hannah Fry (Age 33)
VP, Principal Accounting Officer & Controller
Ms. Justine O'Malley
Senior Vice President of Investor Relations & Corporate Affairs
Ms. Mary J. Grendell
General Counsel & Corporate Secretary

Key Competitors

View All Competitors

Institutional Ownership

Citadel Advisors LLC
Sold 800 shares on 2/15/2024
Ownership: 0.000%

View All Institutional Transactions

TARA Stock Analysis - Frequently Asked Questions

Should I buy or sell Protara Therapeutics stock right now?: 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Protara Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" TARA shares.
View TARA analyst ratings or view top-rated stocks.
What is Protara Therapeutics' stock price target for 2024?: 1 Wall Street research analysts have issued 12-month price targets for Protara Therapeutics' shares. Their TARA share price targets range from $23.00 to $23.00. On average, they predict the company's stock price to reach $23.00 in the next year. This suggests a possible upside of 745.6% from the stock's current price.
View analysts price targets for TARA or view top-rated stocks among Wall Street analysts.
How have TARA shares performed in 2024?: Protara Therapeutics' stock was trading at $1.8751 at the beginning of 2024. Since then, TARA stock has increased by 45.1% and is now trading at $2.72.
View the best growth stocks for 2024 here.
When is Protara Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our TARA earnings forecast.

How were Protara Therapeutics' earnings last quarter?: Protara Therapeutics, Inc. (NASDAQ:TARA) posted its quarterly earnings data on Wednesday, March, 13th. The company reported ($0.90) EPS for the quarter, topping the consensus estimate of ($1.03) by $0.13.
What other stocks do shareholders of Protara Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Protara Therapeutics investors own include Immunic (IMUX), Trevena (TRVN), AIM ImmunoTech (AIM), Chimerix (CMRX), CTI BioPharma (CTIC), Fortress Biotech (FBIO), Genocea Biosciences (GNCA) and Otonomy (OTIC).
How do I buy shares of Protara Therapeutics?: Shares of TARA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:TARA) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Protara Therapeutics (TARA) Stock Price, News & Analysis

Protara Therapeutics MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Protara Therapeutics Stock (NASDAQ:TARA)

TARA Stock Price History

TARA Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Institutional Ownership

TARA Stock Analysis - Frequently Asked Questions

Overall MarketRank^™